CVRx - Gilde Healthcare

CVRx

Venture&Growth
Location

Minneapolis (MN), USA

Neurostimulation
Since: 2016
Venture&Growth

CVRx, Inc. develops, manufactures and sells the BAROSTIM NEO, a minimally-invasive implantable neurostimulator. It has obtained market approval in Europe for use in heart failure and resistant hypertension. In the US, CVRx has obtained approval for the treatment of heart failure symptoms.  The implantable device triggers the body’s sympathetic and para-sympathetic nervous system to treat these conditions and can be adjusted to meet each patient’s individual therapy needs. In the United States and Europe, heart failure is estimated to affect 15 million adults, and is associated with a four-fold increased risk of death and a six to nine times increased risk of sudden cardiac death. The direct and indirect costs of heart failure are estimated to be $32 billion in the United States alone.

CVRx is now publicly listed on the NASDAQ under the ticker symbol CVRX.  The company is based in Minneapolis, Minnesota (US).

More CVRx news

Gilde Healthcare portfolio company CVRx realizes succesful IPO at Nasdaq

CVRx® raises $50 million in new equity financing

CVRx® announces publication of BeAt-HF clinical study results in the journal of the American College of Cardiology

CVRx obtains FDA approval for heart failure neuromodulation device

Gilde Healthcare participates in $93 million equity round for cardiovascular company CVRx